Many hypotheses have been generated regarding this apparent inconsistency, including that Black patients might have a lower incidence of hyperprogressive disease with anti-PD-1/PD-L1 therapy,22 and/or may derive benefit from a higher tumor mutational burden and genomic instability as correlated with smoking status that appears to favor ICI efficacy.37-41. Here, PDCD1 is linked to neoplasm.